Standout Papers

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia 2013 2026 2017 2021 3.8k
  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia (2014)
    Shannon L. Maude, Noelle V. Frey et al. New England Journal of Medicine
  2. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia (2013)
    Stephan A. Grupp, Michael Kalos et al. New England Journal of Medicine
  3. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy (2013)
    David T. Teachey, Susan R. Rheingold et al. Blood
  4. Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531 (2014)
    Alan S. Gamis, Todd A. Alonzo et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 36 from Science/Nature 225 standout
Sub-graph 1 of 15

Citing Papers

CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
A new era of cancer phototherapy: mechanisms and applications
2024 Standout
26 intermediate papers

Works of Richard Aplenc being referenced

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
and 4 more

Author Peers

Author Last Decade Papers Cites
Richard Aplenc 2638 2370 7923 3255 2888 316 13.0k
Edward A. Stadtmauer 6622 808 6730 5066 2130 330 13.7k
Rosemarie Mick 1463 1065 6092 3493 3164 262 14.1k
Andreas Engert 1931 1456 9034 2108 4065 551 20.2k
Marcos de Lima 9003 2801 3438 1916 2821 418 12.4k
Matthew J. Maurer 450 483 4760 4404 1388 476 13.6k
Selina M. Luger 5274 3131 2860 2848 1238 300 9.4k
Daniel J. DeAngelo 8805 4208 4155 6062 1800 438 15.9k
Bipin N. Savani 5766 1840 2873 1054 2620 361 8.7k
Richard J. Jones 7567 1387 4223 3296 3760 330 14.1k
Ofer Shpilberg 3196 791 3637 1814 1475 260 8.9k

All Works

Loading papers...

Rankless by CCL
2026